YOUR BUSINESS AUTHORITY
Springfield, MO
Swiss drugmaker Roche agreed to buy Philadelphia-based Spark Therapeutics for $4.8 billion.
Spark, which creates gene therapies for genetic diseases, is behind the blindness treatment called Luxturna, which costs $425,000 per eye.
"Spark Therapeutics' proven expertise in the entire gene therapy value chain may offer important new opportunities for the treatment of serious diseases," Roche CEO Severin Schwan said in a news release. "Spark Therapeutics' haemophilia A programme could become a new therapeutic option for people living with this disease."
Read more from Business Insider.
Nixa Superintendent Gearl Loden weighs in on A-F grade cards.
SBJ announces executive newsroom hires
Thanksgiving staple recalled at Costco
HBA of Greater Springfield executive officer to retire
Timeshare exit company owner sentenced for tax evasion
Warren Buffett donates $5.5B worth of Berkshire Hathaway shares
Letter to the Editor: No half-baked cake for our kids. No half-baked school grades, either.